High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer
Yıl: 2022 Cilt: 19 Sayı: 3 Sayfa Aralığı: 246 - 256 Metin Dili: İngilizce DOI: 10.4274/tjod.galenos.2022.59558 İndeks Tarihi: 27-10-2022
High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer
Öz: Objective: The current study assesses programmed death-1 (PD-1) receptor expression and CD3, CD4, and CD8 tumor-infiltrating lymphocytes (TILs) in high-grade serous ovarian cancer (HGSOC) and associates our results with neoadjuvant chemotherapy history and disease prognosis. Materials and Methods: We included cases diagnosed with primary HGSOC with biopsy or surgical resection materials in this study. The immunoreactivity of CD3, CD4, CD8, and PD1 was assessed immunohistochemically in tumor tissue. We analyzed TILs in two predetermined groups of high and low TIL. The relationships between clinical characteristics, PD-1, and TIL were assessed. by the χ(2) test or Fisher’s Exact test. We used Kaplan-Meier survival analysis and Cox proportional hazards regression model to the connection between survival and the amounts of TIL, and PD1. Results: Univariate analysis demonstrated that optimal debulking (p<0.001), early International Federation of Gynecology and Obstetrics stage (p=0.046), and higher scores of stromal CD8+ TIL expression (p=0.028) in tumor cells were all substantially correlated with longer disease-free survival (DFS), whereas the remaining variables analyzed, including PD-1 positivity, stromal CD3+, and CD4+ TILs, and intraepithelial CD3+, CD4+, and CD8+ TILs, were not correlated with DFS. Also, univariate analysis revealed that optimal debulking (p=0.010), and higher scores of stromal CD8+ TIL expression (p=0.021) in tumor cells were all substantially correlated with longer overall survival (OS). Conclusion: Higher scores of stromal CD8+ TILs are substantially correlated with DFS and OS in univariate analyses, whereas scores of stromal CD3+ and CD4+ TILs, and intraepithelial CD3+, CD4+, and CD8+ TILs are not correlated with DFS and OS in both univariate and multivariate analyses. Also, we found a significant association between PD-1 positivity and the scores of stromal CD3+ TILs and intraepithelial CD8+ TILs. However, no remarkable relationship was revealed between PD-1 positivity and the survival of HGSOC cases.
Anahtar Kelime: Tümör mikroçevresinde CD8’in yüksek ekspresyonu, yüksek dereceli seröz over kanserinde PD-1 ekspresyonu ve hasta sağkalımı ile ilişkilidir
Öz: Amaç: Çalışmamızın amacı, yüksek dereceli seröz over kanserinde (HGSOC) programlanmış ölüm-1 (PD-1) reseptör ekspresyonunu ve CD3, CD4 ve CD8 tümör infiltre edici lenfositleri (TIL) değerlendirmek ve bulgularımızın neoadjuvan kemoterapi öyküsü ve hastalık prognozu ile ilişkisini incelemektir. Gereç ve Yöntemler: Biyopsi veya cerrahi rezeksiyon materyalleri ile primer HGSOC tanısı alan olgular çalışmaya dahil edildi. CD3, CD4, CD8 ve PD1’in immünoreaktivitesi, tümör dokusunda immünohistokimyasal olarak değerlendirildi. TIL, önceden tanımlanmış iki grup olan düşük ve yüksek TIL grubunda analiz edildi. Klinik özellikler, PD-1 ve TIL arasındaki ilişkiler χ(2) testi veya Fisher’s Exact test ile değerlendirildi. TIL, PD1 ve hayatta kalma arasındaki ilişki için Kaplan-Meier hayatta kalma analizi ve Cox oransal hazard regresyon modeli kullanıldı. Bulgular: Tek değişkenli analiz, tümör hücrelerinde optimal debulking (p<0,001), erken Uluslararası Jinekoloji ve Obstetrik Federasyonu evresi (p=0,046) ve daha yüksek stromal CD8+ TIL ekspresyonu skorlarının (p=0,028) tümünün daha uzun hastalıksız sağkalım (DFS) ile önemli ölçüde ilişkili olduğunu gösterdi; oysa ki kalan değişkenler, PD-1 pozitifliği, stromal CD3+ ve CD4+ TIL’ler ve intraepitelyal CD3+, CD4+ ve CD8+ TIL’ler dahil olmak üzere, analiz edildiğinde DFS ile korele değildi. Ayrıca, tek değişkenli analiz, tümör hücrelerinde optimal debulking (p=0,010) ve daha yüksek stromal CD8+ TIL ekspresyonu skorlarının (p=0,021) tümünün daha uzun genel sağkalım (OS) ile önemli ölçüde ilişkili olduğunu ortaya koydu. Sonuç: Daha yüksek stromal CD8+ TIL skorları, tek değişkenli analizde DFS ve OS ile anlamlı şekilde ilişkiliyken, stromal CD3+ ve CD4+ TIL’lerin ve intraepitelyal CD3+, CD4+ ve CD8+ TIL’lerin skorları, hem tek değişkenli hem de çok değişkenli analizlerde DFS ve OS ile ilişkili değildi. Ayrıca, PD-1 pozitifliği ile stromal CD3+ TIL’lerin ve intraepitelyal CD8+ TIL’lerin skorları arasında anlamlı bir ilişki bulundu. Ancak, PD-1 pozitifliği ile HGSOC hastalarının sağkalımı arasında anlamlı bir ilişki gözlenmedi.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49.
- 2. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ 2020;371:m3773.
- 3. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 2017;41:3-14.
- 4. Akgöl S, Aktürk E, Yıldız Özaydın İ, Ölmez F, Karakaş S, Oğlak SC, et al. Serous Epithelial Ovarian Cancer: Retrospective Analysis of 260 Cases. Aegean J Obstet Gynecol 2021;3:19-21.
- 5. Öcal E, Oğlak SC. The Effect of Lymph Node Dissection on Survival in Patients with Advanced Stage (Stage IIIC and IV) Ovarian Cancer. Medical Journal of Mugla Sitki Kocman University 2020;7:40-4.
- 6. Dinca AL, Bîrla RD, Dinca VG, Marica C, Panaitescu E, Constantinoiu S. Prognostic Factors in Advanced Ovarian Cancer - A Clinical Trial. Chirurgia (Bucur) 2020;115:50-62.
- 7. Jiang Y, Wang C, Zhou S. Targeting tumor microenvironment in ovarian cancer: Premise and promise. Biochim Biophys Acta Rev Cancer 2020;1873:188361.
- 8. Hao J, Yu H, Zhang T, An R, Xue Y. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. Ther Adv Med Oncol 2020;12:1758835920967241.
- 9. Pinto MP, Balmaceda C, Bravo ML, Kato S, Villarroel A, Owen GI, et al. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. Gynecol Oncol 2018;151:10-7.
- 10. Baert T, Vergote I, Coosemans A. Ovarian cancer and the immune system. Gynecol Oncol Rep 2017;19:57-8.
- 11. Wang Q, Lou W, Di W, Wu X. Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int Immunopharmacol 2017;52:7-14.
- 12. Santoiemma PP, Powell DJ. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther 2015;16:807-20.
- 13. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012;124:192-8.
- 14. Turner TB, Buchsbaum DJ, Straughn JM, Randall TD, Arend RC. Ovarian cancer and the immune system - The role of targeted therapies. Gynecol Oncol 2016;142:349-56.
- 15. Li J, Wang J, Chen R, Bai Y, Lu X. The prognostic value of tumorinfiltrating T lymphocytes in ovarian cancer. Oncotarget 2017;8:15621- 31.
- 16. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-44.
- 17. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;143:3460-73.
- 18. Tseng JH, Cowan RA, Zhou Q, Iasonos A, Byrne M, Polcino T, et al. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival? Gynecol Oncol 2018;151:24-31.
- 19. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015;26:259-71.
- 20. Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J, et al. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget 2016;7:30772-80.
- 21. Arman Karakaya Y, Atıgan A, Güler ÖT, Demiray AG, Bir F. The relation of CD3, CD4, CD8 and PD-1 expression with tumor type and prognosis in epithelial ovarian cancers. Ginekol Pol 2021;92:344-51.
- 22. Mlynska A, Vaišnorė R, Rafanavičius V, Jocys S, Janeiko J, Petrauskytė M, et al. A gene signature for immune subtyping of desert, excluded, and inflamed ovarian tumors. Am J Reprod Immunol 2020;84:e13244.
- 23. Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res 2014;20:434-44.
- 24. Yang L, Wang S, Zhang Q, Pan Y, Lv Y, Chen X, et al. Clinical significance of the immune microenvironment in ovarian cancer patients. Mol Omics 2018;14:341-51.
- 25. Hwang C, Lee SJ, Lee JH, Kim KH, Suh DS, Kwon BS, et al. Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. Oncol Lett 2019;17:4557-65.
- 26. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
- 27. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/ regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
- 28. Lo CS, Sanii S, Kroeger DR, Milne K, Talhouk A, Chiu DS, et al. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. Clin Cancer Res 2017;23:925-34.
- 29. Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, et al. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology 2013;2:e26677.
- 30. Webb JR, Milne K, Kroeger DR, Nelson BH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol 2016;141:293-302.
- 31. Deshpande M, Romanski PA, Rosenwaks Z, Gerhardt J. Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability. Cancers (Basel) 2020;12:3319.
- 32. Webb JR, Milne K, Nelson BH. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. Cancer Immunol Res 2015;3:926-35.
- 33. Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 2016;7:13587-98.
- 34. Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2016;7:1486-99.
| APA | Olmez F, Oglak S, ÖLMEZ Ö, Akbayir O, YILMAZ E, akgol s, Konal M, Seyhan N, Kinter A (2022). High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. , 246 - 256. 10.4274/tjod.galenos.2022.59558 |
| Chicago | Olmez Fatma,Oglak Süleyman Cemil,ÖLMEZ ÖMER FATİH,Akbayir Ozgur,YILMAZ ERCAN,akgol sedat,Konal Merve,Seyhan Niyazi alper,Kinter Alp Koray High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. (2022): 246 - 256. 10.4274/tjod.galenos.2022.59558 |
| MLA | Olmez Fatma,Oglak Süleyman Cemil,ÖLMEZ ÖMER FATİH,Akbayir Ozgur,YILMAZ ERCAN,akgol sedat,Konal Merve,Seyhan Niyazi alper,Kinter Alp Koray High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. , 2022, ss.246 - 256. 10.4274/tjod.galenos.2022.59558 |
| AMA | Olmez F,Oglak S,ÖLMEZ Ö,Akbayir O,YILMAZ E,akgol s,Konal M,Seyhan N,Kinter A High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. . 2022; 246 - 256. 10.4274/tjod.galenos.2022.59558 |
| Vancouver | Olmez F,Oglak S,ÖLMEZ Ö,Akbayir O,YILMAZ E,akgol s,Konal M,Seyhan N,Kinter A High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. . 2022; 246 - 256. 10.4274/tjod.galenos.2022.59558 |
| IEEE | Olmez F,Oglak S,ÖLMEZ Ö,Akbayir O,YILMAZ E,akgol s,Konal M,Seyhan N,Kinter A "High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer." , ss.246 - 256, 2022. 10.4274/tjod.galenos.2022.59558 |
| ISNAD | Olmez, Fatma vd. "High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer". (2022), 246-256. https://doi.org/10.4274/tjod.galenos.2022.59558 |
| APA | Olmez F, Oglak S, ÖLMEZ Ö, Akbayir O, YILMAZ E, akgol s, Konal M, Seyhan N, Kinter A (2022). High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. Turkish Journal of Obstetrics and Gynecology, 19(3), 246 - 256. 10.4274/tjod.galenos.2022.59558 |
| Chicago | Olmez Fatma,Oglak Süleyman Cemil,ÖLMEZ ÖMER FATİH,Akbayir Ozgur,YILMAZ ERCAN,akgol sedat,Konal Merve,Seyhan Niyazi alper,Kinter Alp Koray High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. Turkish Journal of Obstetrics and Gynecology 19, no.3 (2022): 246 - 256. 10.4274/tjod.galenos.2022.59558 |
| MLA | Olmez Fatma,Oglak Süleyman Cemil,ÖLMEZ ÖMER FATİH,Akbayir Ozgur,YILMAZ ERCAN,akgol sedat,Konal Merve,Seyhan Niyazi alper,Kinter Alp Koray High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. Turkish Journal of Obstetrics and Gynecology, vol.19, no.3, 2022, ss.246 - 256. 10.4274/tjod.galenos.2022.59558 |
| AMA | Olmez F,Oglak S,ÖLMEZ Ö,Akbayir O,YILMAZ E,akgol s,Konal M,Seyhan N,Kinter A High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. Turkish Journal of Obstetrics and Gynecology. 2022; 19(3): 246 - 256. 10.4274/tjod.galenos.2022.59558 |
| Vancouver | Olmez F,Oglak S,ÖLMEZ Ö,Akbayir O,YILMAZ E,akgol s,Konal M,Seyhan N,Kinter A High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. Turkish Journal of Obstetrics and Gynecology. 2022; 19(3): 246 - 256. 10.4274/tjod.galenos.2022.59558 |
| IEEE | Olmez F,Oglak S,ÖLMEZ Ö,Akbayir O,YILMAZ E,akgol s,Konal M,Seyhan N,Kinter A "High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer." Turkish Journal of Obstetrics and Gynecology, 19, ss.246 - 256, 2022. 10.4274/tjod.galenos.2022.59558 |
| ISNAD | Olmez, Fatma vd. "High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer". Turkish Journal of Obstetrics and Gynecology 19/3 (2022), 246-256. https://doi.org/10.4274/tjod.galenos.2022.59558 |
